Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Kim Christiansen discusses her experiences managing limited mobility and chronic pain from a partial spinal cord injury and Dr Natalie Hoff describes good physical therapy care for patients with chronic migraine headaches.
Differentiating between best palliative care options and the curative and palliative potential of surgery is key to developing dual intentional clarity.
AMA J Ethics. 2021;23(10):E766-771. doi:
10.1001/amajethics.2021.766.
Dr Travis Rieder discusses his own experiences with opioids and the ethical challenges of “legacy patients,” and Dr Stephanie Zaza, president of the American College of Preventive Medicine, discusses the future of opioid research priorities.
Patients can now easily view their health records, so clinicians must consider a reader’s interpretation of how they convey sensitive personal health information. What might this mean for ethics consultants?
AMA J Ethics. 2020;22(9):E784-791. doi:
10.1001/amajethics.2020.784.
This commentary on a case considers a transgender patient’s mental health and risk for DVT in ethical decision making about feminizing gender-affirming hormone therapy.
AMA J Ethics. 2023;25(6):E386-390. doi:
10.1001/amajethics.2023.386.
Beyond consensus that pain is “an unpleasant sensory and emotional experience,” its biology remains poorly understood, and options for its treatment remain frustratingly inadequate.